Landscape of microRNA regulatory network architecture and functional rerouting in cancer
Xu Hua,Yongsheng Li,Sairahul R. Pentaparthi,Daniel J. McGrail,Raymond Zou,Li Guo,Aditya Shrawat,Kara M. Cirillo,Qing Li,Min Xu,Dan Qi,Ashok Singh,Francis McGrath,Jishnu Das,Yunyun Zhou,Alessia Lodi,Gordon B. Mills,S. Gail Eckhardt,Marc L. Mendillo,Stefano Tiziani,Erxi Wu,Jason H. Huang,Nidhi Sahni,S. Stephen Yi,Akshay V. Bhat,Steven B. Andrews,Kyaw Lwin. Aung
DOI: https://doi.org/10.1158/0008-5472.can-20-0371
IF: 11.2
2022-10-22
Cancer Research
Abstract:Somatic mutations are a major source of cancer development, and many driver mutations have been identified in protein coding regions. However, the function of mutations located in microRNAs (miRNAs) and their target binding sites throughout the human genome remains largely unknown. Here, we built detailed cancer-specific miRNA regulatory networks across 30 cancer types to systematically analyze the effect of mutations in miRNAs and their target sites in 3' UTR, CDS, and 5' UTR regions. A total of 3,518,261 mutations from 9,819 samples were mapped to miRNA-gene interactions (mGI). Mutations in miRNAs showed a mutually exclusive pattern with mutations in their target genes in almost all cancer types. A linear regression method identified 148 candidate driver mutations that can significantly perturb miRNA regulatory networks. Driver mutations in 3'UTRs played their roles by altering RNA binding energy and the expression of target genes. Finally, mutated driver gene targets in 3' UTRs were significantly downregulated in cancer and functioned as tumor suppressors during cancer progression, suggesting potential miRNA candidates with significant clinical implications. A user-friendly, open-access web portal (mGI-map) was developed to facilitate further use of this data resource. Together, these results will facilitate novel non-coding biomarker identification and therapeutic drug design targeting the miRNA regulatory network.
oncology